SCHEMBL9926099

SCHEMBL9926099

O=C([C@@H]1CN(S(=O)(=O)c2cc(Cl)c(Cl)s2)C[C@H]1c1ccccc1)N1CCN(c2ccccc2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 1/20 0.51
MAPT P10636 4/20 0.50
LMNA P02545 3/20 0.50
KMT2A Q03164 3/20 0.50
MEN1 O00255 2/20 0.50
ALDH1A1 P00352 1/20 0.50
TSHR P16473 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
SMN1; SMN2 Q16637 4/20 0.47
HTT P42858 2/20 0.47
POLB P06746 3/20 0.43
TDP1 Q9NUW8 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
CHRM1 P11229 3/20 0.41
ADAM10 O14672 1/20 0.41
ERBB2 P04626 1/20 0.41
MMP2 P08253 1/20 0.41
MAPK1 P28482 1/20 0.40
HSD17B10 Q99714 1/20 0.40
MC4R P32245 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5268393 0.92 SMN1; SMN2 (0.50) SIGMAR1MAPTLMNAKMT2AMEN1
SCHEMBL9926069 0.92 SMN1; SMN2 (0.50) SIGMAR1MAPTLMNAKMT2AMEN1
SCHEMBL9926068 0.90 MAPT (0.45) SIGMAR1MAPTLMNAKMT2AMEN1
SCHEMBL13987546 0.90 MAPT (0.47) MAPTLMNAKMT2AMEN1ALDH1A1
SCHEMBL9925999 0.87 SIGMAR1 (0.53) SIGMAR1MAPTLMNAKMT2AMEN1
SCHEMBL9926090 0.86 AR (0.46) HTTPOLBMC4R
SCHEMBL9926111 0.86 MC4R (0.56) LMNAKMT2AMEN1ALDH1A1TSHR
SCHEMBL9925998 0.86 AR (0.46) MAPTKMT2ASMN1; SMN2HSD17B10MC4R
SCHEMBL9926081 0.86 SMN1; SMN2 (0.48) MAPTKMT2AMEN1ALDH1A1TSHR
SCHEMBL5270813 0.86 AR (0.46) MAPTKMT2ASMN1; SMN2HSD17B10MC4R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1836180-B1 SULFONYL PYRROLIDINES, METHOD FOR PRODUCING THE SAME AND THEIR USE AS DRUGS SANOFI SA (FR) 2012-06-13 EP disclosed
US-7468369-B2 Sulfonyl pyrrolidines, method for producing the same and their use as drugs SANOFI-AVENTIS (FR) 2008-12-23 US disclosed
US-7468369-B2 Sulfonyl pyrrolidines, method for producing the same and their use as drugs SANOFI-AVENTIS (FR) 2008-12-23 US disclosed
US-20080045540-A1 SULFONYL PYRROLIDINES, METHOD FOR PRODUCING THE SAME AND THEIR USE AS DRUGS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-02-21 US disclosed
US-20080045540-A1 SULFONYL PYRROLIDINES, METHOD FOR PRODUCING THE SAME AND THEIR USE AS DRUGS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045540-A1 SULFONYL PYRROLIDINES, METHOD FOR PRODUCING THE SAME AND THEIR USE AS DRUGS SLC5A1, SLC5A2, KCNJ1 SIGMAR1 826/4885MAPT 4225/4885LMNA 3961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.